Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
Apr 18 2024
•
By
Derrick Gingery
CBER and CDER have averaged more than 1% quarterly growth since the beginning of FY 2023. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
More from US FDA
More from Agency Leadership